Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

stockpurrrrs Oct. 4 at 11:48 PM

$SLS I'll say it again. 100+ bagger!

0 · Reply

OnTheBalance Oct. 4 at 11:48 PM

$SLS Let shareholders decide :).. leave me out of it 😂 I am pretty satisfied with Dr. Stergiou's recent posts, and am pretty sure that 4 KOLs will not be joining the call to discuss that 80 is 60+20, nor will they be there only to discuss SLS009 plans. Dr. Stergiou's energy is about GPS progress.

0 · Reply

Gps_100X_ROI_Potential Oct. 4 at 11:25 PM

$SLS Funny to see short scumbags downplaying Gps/SLS Now that its Obvious Gps is Getting Fda approval and results are coming - this month. Here is an analyst at a previous meeting, asking Dr. Jamy the Key Question: ’… that the expected survival in CR2 is 6 to 8 months. And this is-- I just want to ask, is this sort of based on the previously published literature, which we see like 5 years, 10 years ago, or this is from your sort of current experience? And what's your estimation - based on your experience, based on the patients that you see in CR2 -- what is the longest survival you saw in CR2 in your practice?’

0 · Reply

RealImbackbears Oct. 4 at 11:17 PM

$SLS pediatric leukemia patient Thanks President Trump https://youtube.com/shorts/5smz1nzv2oc?si=jpfcZtY4DeHqQT0y

0 · Reply

FatherofTrades Oct. 4 at 11:17 PM

$SLS

0 · Reply

EddieH2020 Oct. 4 at 10:26 PM

$SLS

0 · Reply

OnTheBalance Oct. 4 at 10:18 PM

$SLS another New to Trade Turdistan donkey on board ...bahahaha

0 · Reply

wanderlust222 Oct. 4 at 10:16 PM

$SLS if I become a millionaire from SLS, I'm taking a trip to Greece. Who's going with me?

2 · Reply

wanderlust222 Oct. 4 at 10:11 PM

$SLS I'm seeing a lot of posts saying something to the effect of, "this might be a 10xer, but a 50xer is unreasonable." It's good to not be focused on shorts or squeezes, but let's not forget the FACT this company is 20 million buys suppressed. If 20 million buys hit the tape, what do you think will happen to the SP? It could raise it 100s of %, and now a 10x on data IS a 50x or whatever.

2 · Reply

FatherofTrades Oct. 4 at 9:54 PM

$SLS

2 · Reply

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 2 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 3 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 4 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 4 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 5 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 5 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 5 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 5 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 6 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 6 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 7 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 8 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 8 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 9 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 9 months ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 10 months ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 10 months ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 11 months ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 11 months ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 11 months ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 11 months ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 1 year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 1 year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Jan 25, 2024, 8:45 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

Jan 9, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Jan 4, 2024, 9:01 AM EST - 1 year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Jan 3, 2024, 8:05 PM EST - 1 year ago

SELLAS Life Sciences Announces Proposed Public Offering

Jan 3, 2024, 7:30 AM EST - 1 year ago

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

stockpurrrrs Oct. 4 at 11:48 PM

$SLS I'll say it again. 100+ bagger!

0 · Reply

OnTheBalance Oct. 4 at 11:48 PM

0 · Reply

Gps_100X_ROI_Potential Oct. 4 at 11:25 PM

0 · Reply

RealImbackbears Oct. 4 at 11:17 PM

$SLS pediatric leukemia patient Thanks President Trump https://youtube.com/shorts/5smz1nzv2oc?si=jpfcZtY4DeHqQT0y

0 · Reply

FatherofTrades Oct. 4 at 11:17 PM

$SLS

0 · Reply

EddieH2020 Oct. 4 at 10:26 PM

$SLS

0 · Reply

OnTheBalance Oct. 4 at 10:18 PM

$SLS another New to Trade Turdistan donkey on board ...bahahaha

0 · Reply

wanderlust222 Oct. 4 at 10:16 PM

$SLS if I become a millionaire from SLS, I'm taking a trip to Greece. Who's going with me?

2 · Reply

wanderlust222 Oct. 4 at 10:11 PM

2 · Reply

FatherofTrades Oct. 4 at 9:54 PM

$SLS

2 · Reply

GollumSmeagol Oct. 4 at 8:26 PM

$SLS New here and trading the data catalyst. Anyone else think some of these valuations being thrown around seem completely out of reality? Honestly if data is good I could see it trade in a range of $4-$10. Slim chance over $10. Capping post data MC around 1B, jmho.

8 · Reply

new_to_trade2 Oct. 4 at 8:16 PM

$SLS ANY DAY NOW THEY"LL INVITE ME TO THE SHAREHOLDER MEETING ANY DAY NOW

1 · Reply

Jomppaaz Oct. 4 at 8:12 PM

$SLS Okay, @new_to_trade2 is a new name for the list 🤦‍♂️ Get a life bitch.

1 · Reply

vlucky16 Oct. 4 at 8:12 PM

$SLS It's for sure thing if you shake the trees around SLS Bears fall out of the trees. I love it when that happens.

0 · Reply

new_to_trade2 Oct. 4 at 7:54 PM

$CAPR $SLS -56% WOW Bears are always right

0 · Reply

new_to_trade2 Oct. 4 at 7:52 PM

$IOVA $SLS The biggest bull on this forum thinks IOVA is getting bought out. Buy it at a -77% discount! SLS too getting that discount soon!

3 · Reply

new_to_trade2 Oct. 4 at 7:37 PM

$SLS Angelo’s the scamgelos ladies and gentlemen.

2 · Reply

Gps_100X_ROI_Potential Oct. 4 at 7:14 PM

$SLS … that the expected survival in CR2 is 6 to 8 months. And this is-- I just want to ask, is this sort of based on the previously published literature, which we see like 5 years, 10 years ago, or this is from your sort of current experience? And what's your estimation - based on your experience, based on the patients that you see in CR2 -- what is the longest survival you saw in CR2 in your practice?

0 · Reply

OnTheBalance Oct. 4 at 6:40 PM

$SLS Calls Open Interest now represents 42.2733 Million Shares Puts Open Interest now represents 699.3K Shares The new puts were taken out for January 2026... IMHO, these are the fake games played out by some HF that is in "trouble" trying to create false fears. Old game that Cramer described well a long time ago when he was still pretty sharp from his actual trading days. The Sellas BOD is not totally stupid, and are now shifting to next chapter of their playbook... "SURPRISE" Strategists like Laura Zhu are useful. and Sun Tzu.. The Art of War.

2 · Reply

Gps_100X_ROI_Potential Oct. 4 at 6:16 PM

$SLS - Any Day Now is Here. I've likely been here, invested, as long as anyone, and I AM Pumped, never been MORE Excited to have a fully Loaded Nut Sack of these Cheap SLS shares. As I've been posting for the last few weeks, given all we know about Enrollment timelines and Os data, the 80th event Likely occurred already, probably in the last weeks - and the Ceo's positive statements online, and the Meeting Set for the 29th Confirms it. The IDMC likely notified the Ceo of the 80th, and while in doing so, gave the CEO the Good Word - and said Top Line would be incoming Oct 26th/27th - hence the KOL set for the 29th.

1 · Reply

JdlawVT40 Oct. 4 at 6:06 PM

$SLS Interesting when the weekend is not as much fun as the trading weekdays.

1 · Reply

vlucky16 Oct. 4 at 5:54 PM

$SLS GPS 6b+ MC. 32 share price. As a BO 3 x6b = 18b. or 97 a share Did I forget something??? 009 inhibitor one of a kind drug platform better results in AML than Keytruda. (Goosebumps all over!!!). Potential across the board cancer treatments including pediatrics. Value let's value as Keytruda 29b a year in revenue. As BO 3 x 29b = 87b or 470 a share 97 + 470 = 567 a share. Can BP pay this??? 35b+a year in revenue for 10+ years 350billion ? Will BP pay half of what the BO standard is 283 a share. Getting Hot!!!

6 · Reply

Market Cap	180.06M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,417,200
Avg Vol	2,037,340
Day's Range	N/A - N/A
Shares Out	105.30M
Stochastic %K	98%
Beta	2.62
Analysts	Strong Sell
Price Target	$6.83